Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

MitomiRs: new emerging microRNAs in mitochondrial dysfunction and cardiovascular disease

Hypertension Research volume 43, pages 851–853 (2020)Cite this article

Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortality in developed countries. CVDs are a group of disorders of the heart and blood vessels. They include hypertension, atherosclerosis, myocardial infarction, ischemia/reperfusion injury, stroke, and heart failure. The molecular mechanisms underlying the complex pathophysiology that leads to CVDs are not fully understood [1]. Therefore, identifying the common molecular mechanisms underlying CVDs will aid in early and accurate diagnosis, which could result in the initiation of an effective therapy and a reduced mortality rate.

Cardiomyocytes are rich in mitochondria, which are the major cellular powerhouse producing >95% of the cell’s energy in the form of adenosine triphosphate (ATP). In addition to energy production, mitochondria are the major site of reactive oxygen species (ROS) production. Accumulated evidence also suggests that mitochondria are critical for heart development in mammals [2]. Mitochondrial dysfunction plays a major role in the pathogenesis of CVDs, such as hypertension, atherosclerosis, ischemia-reperfusion injury, diabetes, cardiac hypertrophy, and heart failure, due to the uncontrolled production of ROS. Therefore, early control of mitochondrial dysfunction is a crucial step in the treatment of CVDs [3].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Soler-Botija C, Carolina Gálvez-Montón C, Bayés-Genís A. Epigenetic biomarkers in cardiovascular diseases. Front Genet. 2019;10:950.

    Article  CAS  Google Scholar 

  2. Zhao Q, Sun Q, Zhou L, Liu K, Jiao K. Complex regulation of mitochondrial function during cardiac development. J Am Heart Assoc. 2019;8:e012731.

    Article  CAS  Google Scholar 

  3. Siasos G, Tsigkou V, Kosmopoulos M, Theodosiadis D, Simantiris S, Tagkou NM, et al. Mitochondria and cardiovascular diseases-from pathophysiology to treatment. Ann Transl Med. 2018;6:256.

    Article  Google Scholar 

  4. Wang X, Song C, Zhou X, Han X, Li J, Wang Z, et al. Mitochondria associated microRNA expression profiling of heart failure. Biomed Res Int. 2017;2017:4042509.

    PubMed  PubMed Central  Google Scholar 

  5. Machado IF, Teodoro JS, Palmeira CM, Rolo A. miR 378a: a new emerging microRNA in metabolism. Cell Mol Life Sci. 2019. https://doi.org/10.1007/s00018-019-03375-z.

  6. Li H, Dai B, Fan J, Chen C, Nie X, Yin Z, et al. The different roles of miRNA-92a-2-5p and let-7b-5p in mitochondrial translation in db/db mice. Mol Ther Nucleic Acids. 2019;6:424–35.

    Article  Google Scholar 

  7. Yan K, An T, Zhai M, Huang Y, Wang Q, Wang Y. et al. Mitochondrial miR-762 regulates apoptosis and myocardial infarction by impairing ND2. Cell Death Dis. 2019;24:500

    Article  Google Scholar 

  8. Kontaraki JE, Marketou ME, Zacharis EA, Parthenakis FI, Vardas PE. Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension. J Hum Hypertens. 2014;28:510–6.

    Article  CAS  Google Scholar 

  9. Song R, Hu XQ, Zhang L. Mitochondrial MiRNA in cardiovascular function and disease. Cells. 2019;8:E1475.

    Article  Google Scholar 

  10. Li J, Li Y, Jiao J, Wang J, Li Y, Qin D, et al. Mitofusin 1 is negatively regulated by microRNA 140 in cardiomyocyte apoptosis. Mol Cell Biol. 2014;34:1788–99.

    Article  Google Scholar 

  11. Macgregor-Das AM, Das S. A microRNA’s journey to the center of the mitochondria. Am J Physiol Heart Circ Physiol. 2018;315:H206–H215.

    Article  CAS  Google Scholar 

  12. Li X, Wei Y, Wang Z. microRNA-21 and hypertension. Hypertens Res. 2018;4:649–61.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. BRULAC-DRC, Saveetha Dental College & Hospital, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, Chennai, India

    Arumugam Paramasivam & Jayaseelan Vijayashree Priyadharsini

Authors
  1. Arumugam Paramasivam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jayaseelan Vijayashree Priyadharsini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arumugam Paramasivam.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paramasivam, A., Vijayashree Priyadharsini, J. MitomiRs: new emerging microRNAs in mitochondrial dysfunction and cardiovascular disease. Hypertens Res 43, 851–853 (2020). https://doi.org/10.1038/s41440-020-0423-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-020-0423-3

Search

Advanced search

Quick links